Structure Therapeutics (GPCR) Equity Ratio (2022 - 2026)

Quarterly Equity Ratio rose 0.83% to 0.96 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.96 through Mar 2026, up 0.83% year-over-year, with the annual reading at 0.96 for FY2025, 0.0% changed from the prior year.

Structure Therapeutics' Equity Ratio history spans 5 years, with the latest figure at 0.96 for Q1 2026.

  • Equity Ratio came in at 0.96 for Q1 2026, roughly flat from 0.96 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.97 in Q2 2024 to a low of 1.18 in Q4 2022.
  • The 5-year median for Equity Ratio is 0.95 (2025), against an average of 0.79.
  • Year-over-year, Equity Ratio surged 179.86% in 2023 and then decreased 3.71% in 2025.
  • Structure Therapeutics' Equity Ratio stood at 1.18 in 2022, then soared by 179.86% to 0.94 in 2023, then increased by 1.88% to 0.96 in 2024, then decreased by 0.0% to 0.96 in 2025, then grew by 0.23% to 0.96 in 2026.
  • Per Business Quant, the three most recent readings for GPCR's Equity Ratio are 0.96 (Q1 2026), 0.96 (Q4 2025), and 0.93 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 0.04
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 0.42
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 0.73
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.77
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 0.21
10 Structure Therapeutics 8.43 Bn 8.43 Bn - 0.96

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.96
Dec 31, 2025 0.96
Sep 30, 2025 0.93
Jun 30, 2025 0.95
Mar 31, 2025 0.95
Dec 31, 2024 0.96
Sep 30, 2024 0.96
Jun 30, 2024 0.97
Mar 31, 2024 0.94
Dec 31, 2023 0.94
Sep 30, 2023 0.89
Jun 30, 2023 0.93
Mar 31, 2023 0.96
Dec 31, 2022 -1.18